Welcome to CDC Stacks | Maternal Highly Active Antiretroviral Therapy and Child HIV-free Survival in Malawi, 2004-2009 - 38065 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Maternal Highly Active Antiretroviral Therapy and Child HIV-free Survival in Malawi, 2004-2009
  • Published Date:
    Mar 2016
  • Source:
    Matern Child Health J. 20(3):542-549.


Public Access Version Available on: March 01, 2017 information icon
Please check back on the date listed above.
Details:
  • Pubmed ID:
    26525557
  • Pubmed Central ID:
    PMC4754130
  • Funding:
    5 U50 PS022061-05/PS/NCHHSTP CDC HHS/United States
    U50 PS022061/PS/NCHHSTP CDC HHS/United States
    U50/CC0222061/CC/ODCDC CDC HHS/United States
  • Document Type:
  • Collection(s):
  • Description:
    Objectives

    Highly active antiretroviral therapy (HAART) provision to eligible HIV-infected pregnant and post-partum women is critical for optimizing maternal health. We assessed the impact of maternal HAART on HIV-free survival of breastfed infants in Malawi.

    Methods

    The Post-Exposure Prophylaxis of Infants (PEPI)-Malawi trial (2004-2009) enrolled mothers/infants during labor or immediately post-partum to evaluate 14-week extended infant antiretroviral prophylaxis for preventing HIV transmission through breastfeeding. Mothers meeting national HAART guidelines were referred for therapy. Child HIV-free survival--survival without HIV infection --was compared by maternal HAART status.

    Results

    Overall, 3,022 mother-infant pairs contributed 4,214 infant/person-years (PY) at-risk for HIV infection or death, with 532 events (incidence 12.6/100 PY, 95% confidence interval [CI] 11.6-13.7). During follow-up, 349 mothers were HAART initiated; 581 remained HAART naïve with CD4 cell counts <250 cells/mm3, and 2,092 were never HAART-eligible. By three months, 11% of infants with HAART naïve mothers (CD4<250) were infected with HIV or died versus 7% of infants of HAART-initiated mothers and 4% of infants of HAART-ineligible mothers. Maternal HAART was associated with a 46% reduction in infant HIV infection or death as compared to infants with HAART naïve mothers (CD4<250) (adjusted Hazards Ratio: 0.54,95% CI 0.36-0.81). Among HIV-exposed, uninfected infants, breastfeeding, but not HAART, was significantly associated with decreased child mortality.

    Conclusions

    HIV infection and mortality are high during the first 3 months post-partum in infants of mothers with advanced HIV, and rapid maternal HAART initiation can significantly improve HIV-related infant outcomes.

  • Supporting Files:
    No Additional Files